Amedisys Inc (AMED)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	-9,747	2,648	2,330	112,184	118,609	120,939	140,303	190,873	209,072	220,125	247,100	201,625	183,557	166,157	128,276	127,302	126,800	126,600	123,900	123,500
Total assets	US$ in thousands	2,060,170	2,027,420	1,982,400	1,946,960	1,976,240	1,982,130	2,000,990	1,908,390	1,856,970	1,937,640	1,599,560	1,573,210	1,567,200	1,602,720	1,645,490	1,440,080	1,262,740	1,212,380	1,205,860	1,184,240
ROA		-0.47%	0.13%	0.12%	5.76%	6.00%	6.10%	7.01%	10.00%	11.26%	11.36%	15.45%	12.82%	11.71%	10.37%	7.80%	8.84%	10.04%	10.44%	10.27%	10.43%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $-9,747K ÷ $2,060,170K
= -0.47%

To analyze Amedisys Inc.'s return on assets (ROA) based on the provided data, we can observe significant fluctuations in ROA over the past eight quarters.

In Q1 2022, the ROA was 10.00%, indicating that the company generated $0.10 in net income for every dollar of assets it possessed. This high ROA suggests efficient asset utilization and profitability during that period.

However, the ROA sharply declined in subsequent quarters, reaching 7.01% in Q2 2022 and further dropping to 6.10% in Q3 2022. The downward trend continued in Q4 2022 with an ROA of 6.00%, representing lower profitability relative to the previous quarters.

The trend of decreasing ROA persisted into 2023, with Q1 2023 showing a considerable drop to 5.76%. This decline may raise concern about the company's ability to generate profits from its assets efficiently.

Subsequently, in Q2 and Q3 2023, the ROA remained relatively stable at 0.12% and 0.13%, respectively. However, in Q4 2023, there was a notable decrease as the ROA turned negative at -0.47%. A negative ROA implies that the company experienced a loss relative to its asset base during that period.

Overall, the fluctuating ROA over the analyzed quarters indicates varying levels of asset efficiency and profitability for Amedisys Inc. The negative ROA in Q4 2023 raises concerns about the company's financial performance and the need for further investigation into the factors affecting its profitability and asset utilization.